![]() | Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (702kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-764058
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.76405
Zusammenfassung
Life expectancy of patients with severe transfusion-dependent beta-thalassemia (TDT) remains below that of the general population. Allogenic hematopoietic stem cell transplantation (HSCT) is the standard curative treatment. Due to the paucity of matched donor (MD) availability, haploidentical HSCT (haplo-HSCT) is a reasonable alternative. Twenty patients with TDT (median age 10 years; range 2–23) ...
